This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Novartis Pharma Schweiz AG.
Reference
Schur N, et al. Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland. PharmacoEconomics : 1 Apr 2021. Available from: URL: https://doi.org/10.1007/s40273-021-01023-8
Rights and permissions
About this article
Cite this article
Siponimod "affordable" for treatment of active secondary progressive MS in Switzerland. PharmacoEcon Outcomes News 876, 31 (2021). https://doi.org/10.1007/s40274-021-7645-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7645-8